

P&T Motion History
Biologic Drugs for Asthma and Urticaria, Biologics for Non-asthma Conditions

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
benralizumab dupilumab* mepolizumab omalizumab	<p>Biologics for non-asthma conditions: After considering the evidence of safety, efficacy and special populations for the treatment of their FDA approved indications excluding asthma, I move that benralizumab, dupilumab, mepolizumab, omalizumab are safe and efficacious for the treatment of their approved indications. Benralizumab, dupilumab, mepolizumab, omalizumab can be subject to therapeutic interchange in the Washington preferred drug list for their FDA approved indications excluding asthma.</p> <p>Motion: Beste 2nd: Weiland</p>	December 11, 2024	N/A	N/A	Passed unanimous
dupilumab* mepolizumab omalizumab	<p>Biologics for non-asthma conditions: After considering the evidence of safety, efficacy and special populations for the treatment of their FDA approved indications excluding asthma, I move that dupilumab, mepolizumab, omalizumab are safe and efficacious for the treatment of their approved indications. Dupilumab, mepolizumab, omalizumab can be subject to therapeutic interchange in the Washington preferred drug list for their FDA approved indications excluding asthma.</p> <p>Motion: Flatebo 2nd: Chawla</p>	October 18, 2023	Yes Flynn Chawla	Yes MacKay Buccola	Passed unanimous

Bold = new this update

Orange* = Categorized under Atopic Dermatitis on WA PDL

12/10/2024